Amedisys (AMED) Stock Price, News & Analysis

Company Overview

Amedisys is a leading provider of home health, hospice and personal care services in the United States. The company offers a range of clinical and supportive care solutions designed to help patients recover in the comfort of their homes or receive compassionate end-of-life support. Its service lines include skilled nursing, physical and occupational therapy, speech therapy, social work and hospice care, as well as home-based palliative care and telehealth monitoring. Amedisys emphasizes personalized care plans and multidisciplinary care teams to address both the clinical and emotional needs of patients and their families.

Founded in 1982 and headquartered in Baton Rouge, Louisiana, Amedisys has grown through a combination of organic expansion and targeted acquisitions. The company operates more than 400 care centers across over 30 states, serving urban, suburban and rural communities. Amedisys continually invests in clinical technology, electronic medical records and remote monitoring tools to enhance care coordination, improve patient outcomes and streamline communication among clinicians, patients and caregivers.

Throughout its history, Amedisys has focused on quality measures and regulatory compliance, earning accreditation and high marks from industry organizations. The company’s home health segment delivers post-acute care for patients with acute or chronic conditions, while its hospice segment provides emotional, spiritual and physical support for individuals facing terminal illness. Amedisys’s personal care services assist patients with activities of daily living, medication reminders and companionship, helping seniors and individuals with disabilities maintain independence.

Under the leadership of President and Chief Executive Officer Steve Stacy, Amedisys continues to pursue a strategy centered on patient-first care, strategic partnerships and community outreach. The executive team includes seasoned professionals in clinical operations, finance and quality assurance who guide initiatives in workforce development, regulatory affairs and innovation. By combining local presence with national scale, Amedisys aims to deliver cost-effective, high-quality care and meet evolving demand for home-based health services.

Key Stats

• Today's Range: $97.55 to $98.01
• 50-Day Range: $93.43 to $98.39
• 52-Week Range: $82.15 to $98.95
• Volume: 290,582 shs
• Average Volume: 412,703 shs
• Market Capitalization: $3.22 billion
• P/E Ratio: 21.57
• Dividend Yield: N/A
• Price Target: $100.75
• Consensus Rating: Hold

Amedisys Stock Analysis - MarketRank™

Amedisys scored higher than 59% of companies evaluated by MarketBeat, and ranked 407th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Amedisys has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Amedisys has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.00%

Earnings Growth

Earnings for Amedisys are expected to grow by 10.00% in the coming year, from $4.40 to $4.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amedisys is 36.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amedisys is 36.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.32.

Price to Earnings Growth Ratio

Amedisys has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amedisys has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.77% of the float of Amedisys has been sold short.

Short Interest Ratio / Days to Cover

Amedisys has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Amedisys has recently increased by 9.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amedisys does not currently pay a dividend.

Dividend Growth

Amedisys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 5.0 / 5
• Environmental Score: -0.61

Percentage of Shares Shorted

6.77% of the float of Amedisys has been sold short.

Short Interest Ratio / Days to Cover

Amedisys has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in Amedisys has recently increased by 9.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.25

News Sentiment

Amedisys has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Amedisys this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amedisys insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Amedisys is held by insiders.

Percentage Held by Institutions

94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMED Stock Analysis - Frequently Asked Questions

How have AMED shares performed this year?

Amedisys' stock was trading at $90.79 on January 1st, 2025. Since then, AMED stock has increased by 7.9% and is now trading at $97.97.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its earnings results on Wednesday, April, 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. The business's quarterly revenue was up 4.1% on a year-over-year basis.

Who are Amedisys' major shareholders?

Amedisys' top institutional shareholders include State of Alaska Department of Revenue (0.06%), Public Employees Retirement System of Ohio (0.06%), Parallel Advisors LLC (0.03%) and Exchange Traded Concepts LLC (0.03%).
View institutional ownership trends.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NASDAQ:AMED
• CIK: 896262
• Web: www.amedisys.com
• Phone: (225) 292-2031
• Fax: 225-292-8163
• Employees: 19,000
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Amedisys: $100.75
• High Price Target: $101.00
• Low Price Target: $100.00
• Potential Upside/Downside: +2.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.71
• Trailing P/E Ratio: 36.11
• Forward P/E Ratio: 22.24
• P/E Growth: 1.32
• Net Income: $43.23 million
• Net Margins: 3.79%
• Pretax Margin: 6.33%
• Return on Equity: 12.52%
• Return on Assets: 7.01%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.29
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $2.35 billion
• Price / Sales: 1.37
• Cash Flow: $6.26 per share
• Price / Cash Flow: 15.64
• Book Value: $36.03 per share
• Price / Book: 2.72

Miscellaneous

• Outstanding Shares: 32,820,000
• Free Float: 32,131,000
• Market Cap: $3.21 billion
• Optionable: Optionable
• Beta: 0.94